Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Telephone:||+44 (0)1223 760 339|
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise offers support to all of the University’s research fields, from science, technology, engineering, maths and medicine to the arts, humanities and social sciences. It is through us that many of the University’s inventions and ideas are protected, licences and consultancy contracts are negotiated, and funding is acquired by start-ups and spin-outs.
Silicon Microgravity (SMG), a spin-out from both BP and the University of Cambridge, has raised $7 million from IP Group, Parkwalk, BP Ventures and Cambridge Enterprise.
12 June 2018Read in full
Microbiotica, a Cambridge Innovation Capital portfolio company, has entered into a multi-year strategic collaboration with Genentech worth up to $534 million. The companies will work together to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).
7 June 2018Read in full
Cambridge Enterprise, the Cambridge Angels and Cambridge Capital Group have completed an initial round of investment in Sorex Sensors Limited, a spin-out company from the Department of Engineering at the University of Cambridge.
4 June 2018Read in full
Cambridge Enterprise, the research commercialisation arm of the University of Cambridge, has signed an agreement with one of China’s largest universities to encourage innovation and entrepreneurship in one of China’s fastest-growing high-tech clusters.
1 June 2018Read in full
An annual data review published by Global University Venturing reports that University of Cambridge spin-outs raised $2,216m in capital for 2013-17, putting it at the top of the global list of universities. The article also reports that in this period Cambridge’s spin-outs closed 96 deals, making it second only to Stanford University in total number of deals, though ahead of it in total capital raised.
29 May 2018Read in full
Paragraf, the graphene technology development company, a recent spin out from the University of Cambridge, has closed a £2.9 million seed round to support the development of its first major products. The round is led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, with the participation of Parkwalk Advisors, Amadeus Capital Partners, IQ Capital Partners and angel investors.
1 May 2018Read in full
Aurelius Environmental, part of Aurelius Holdings, and Dr Vasant Kumar from the University of Cambridge Department of Materials Science and Metallurgy, have won a grant worth over 1.3 million Euros to develop a novel hydrometallurgical process.
29 August 2017Read in full
Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and specialist growth factor manufacturer Qkine Ltd have signed a key licensing deal for Activin A production technology.
7 August 2017Read in full
Evotec AG announced an integrated drug discovery collaboration with STORM Therapeutics to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. The focus will be on a range of newly discovered RNA modulating enzyme targets.
28 July 2017Read in full
Sphere Fluidics Limited and its partners have just won a £1 million grant to develop a novel automated single cell genome engineering platform.
17 July 2017Read in full
10 Sep 2018West Cambridge Site
This five day course of lectures, workshops and visits in Cambridge, UK is aimed at those from anywhere in the world who wish to understand the basics of how new ideas and research results are commercialised at the University of Cambridge and in the wider Cambridge Cluster.